Swiss pharma giant Novartis is changing up its massive R&D organization in hopes of squeezing out some savings while betting big on new medicines.
Using a "systems vaccinology" approach, researchers at Case Western Reserve University School of Medicine and Merck Research Laboratories have published findings that suggest a new way to predict and enhance vaccine effectiveness, in particular with hepatitis B vaccination.
Startup Codiak BioSciences got off the ground in November with ambitious plans to turn exosomes into cancer therapies and venture commitments totaling more than $80 million. Now the Cambridge, MA, company has boosted its funding total to $92 million, extending its runway as it works through early-stage R&D.
A team of researchers in Massachusetts is developing a two-in-one nanoparticle that delivers both a photodynamic therapy and a molecular therapy to treat highly resistant tumors--such as those associated with pancreatic cancer--with decreased toxicity.
Researchers at the University of North Carolina have developed a method of drug delivery using exosomes to protect cancer drugs in the body before they reach their target, effectively cutting the necessary dose.
Belgian biotech Galapagos is shutting down an ulcerative colitis program after its top prospect failed to make a difference in a Phase II trial, putting off plans for late-stage development as the company weighs whether to move forward in another disease.
University of Wisconsin-Madison spinout Co-D is deploying its polymeric micelle drug delivery platform with the aim of commercializing a failed Bristol-Myers Squibb cancer drug. So-called Triolimus boasts FDA's orphan drug designation to treat the rare blood vessel cancer angiosarcoma, a milestone that will accelerate its path to FDA approval (or rejection).
As the Zika virus continues to grab headlines and its spread threatens, governments and industry are urgently committing resources and analyzing vaccine development options.
Kyoto University and Panasonic have revealed a novel vital-sign-sensing technology that's based on radar. This enables the system to remotely detect heart rate and heartbeat interval without any sensors being placed on the patient's body. The accuracy of the system is on par with electrocardiographs.
Cedars-Sinai is planning to trial the use of Fitbit Charge HR activity trackers to gauge the suitability of cancer patients for certain treatments, MobiHealthNews reports.